Amit T, Barkey R J, Gavish M, Youdim M B
Endocrinology. 1984 Feb;114(2):545-52. doi: 10.1210/endo-114-2-545.
A soluble PRL receptor has been identified in the 100,000 X g supernatant from homogenates of lungs and livers of male and female rats treated with either estradiol (E2; 2 mg kg-1 day-1 for 7 days, sc) or ovine PRL (oPRL; 0.1 mg kg-1 day-1 for 14 days, sc). Fifty percent of the total PRL-binding activity in the liver homogenate of E2-treated male rats was found in the supernatant fraction, and only 12% in intact female rats. The soluble PRL receptor has the same specificity, protein dependence, and binding affinity (Ka = 2.8 X 10(9) M-1) characteristics as the membrane-bound receptor. A sheep anti-PRL-receptor antiserum specifically inhibited the binding of [125I]iodo-oPRL to the soluble PRL receptor. Column chromatography on Sepharose 6B revealed a single peak of [125I]iodo-oPRL-receptor complex from liver of E2-treated rats, having a mol wt of 340,000, whereas the 100,000 X g supernatant from lungs and livers of oPRL-treated rats revealed two specific peaks of [125I]iodo-oPRL complex with mol wts of 340,000 (A) and 165,000 (B), respectively. Peak A represented 25% and 27% and peak B, 35% and 49% of the total column radioactivity for liver and lung 100,000 X g supernatant fraction, respectively. Peak B coeluted with a rabbit anti-oPRL antiserum, suggesting that it is a PRL antibody. Anti-PRL-receptor antibody reduced the radioactivity associated with peak A but not peak B. Heat inactivation at 60 C (30 min) resulted in a complete loss of binding in peak A without affecting peak B. The results indicate that the soluble PRL-binding sites, increased in rat lung and liver after treatment with oPRL or E2, may represent an intermediate step in new receptor synthesis before incorporation into the membrane.
在经雌二醇(E2;2mg/kg体重,皮下注射,每日1次,共7天)或绵羊催乳素(oPRL;0.1mg/kg体重,皮下注射,每日1次,共14天)处理的雄性和雌性大鼠的肺和肝匀浆的100,000×g上清液中,已鉴定出一种可溶性催乳素受体。在E2处理的雄性大鼠肝匀浆中,50%的总催乳素结合活性存在于上清液部分,而在未处理的雌性大鼠中仅为12%。可溶性催乳素受体具有与膜结合受体相同的特异性、蛋白质依赖性和结合亲和力(Ka = 2.8×10⁹M⁻¹)特征。羊抗催乳素受体抗血清可特异性抑制[¹²⁵I]碘-oPRL与可溶性催乳素受体的结合。在Sepharose 6B柱上进行层析,发现来自E2处理大鼠肝脏的[¹²⁵I]碘-oPRL-受体复合物有一个单一峰,分子量为340,000,而来自oPRL处理大鼠肺和肝的100,000×g上清液显示出[¹²⁵I]碘-oPRL复合物的两个特异性峰,分子量分别为340,000(A)和165,000(B)。峰A分别占肝脏和肺100,000×g上清液部分总柱放射性的25%和27%,峰B分别占35%和49%。峰B与兔抗oPRL抗血清共洗脱,表明它是一种催乳素抗体。抗催乳素受体抗体降低了与峰A相关的放射性,但不影响峰B。60℃(30分钟)加热灭活导致峰A的结合完全丧失,而不影响峰B。结果表明,经oPRL或E2处理后大鼠肺和肝中增加的可溶性催乳素结合位点可能代表新受体合成并整合到膜之前的一个中间步骤。